Silvia Marsoni Selected Research

Disease Progression

12/2020	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.
1/2020	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
1/2020	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
6/2016	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
7/2015	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
5/2012	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Silvia Marsoni Research Topics

Disease

34	Neoplasms (Cancer) 02/2024 - 01/2003
31	Colorectal Neoplasms (Colorectal Cancer) 02/2024 - 11/2011
6	Colonic Neoplasms (Colon Cancer) 11/2021 - 05/2004
6	Disease Progression 12/2020 - 05/2012
5	Carcinoma (Carcinomatosis) 01/2020 - 01/2003
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 10/2011
3	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2020
3	Ovarian Neoplasms (Ovarian Cancer) 06/2012 - 03/2005
2	Diarrhea 01/2021 - 08/2013
2	Vomiting 01/2021 - 08/2013
2	Thrombocytopenia (Thrombopenia) 01/2021 - 08/2013
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 11/2019
2	Neutropenia 01/2021 - 03/2005
2	Nausea 01/2021 - 08/2013
2	Melanoma (Melanoma, Malignant) 01/2021 - 01/2020
2	Lung Neoplasms (Lung Cancer) 01/2019 - 01/2018
2	Exanthema (Rash) 06/2016 - 04/2010
2	Asthenia 09/2013 - 03/2005
2	Microsatellite Instability 06/2011 - 07/2010
2	Breast Neoplasms (Breast Cancer) 01/2011 - 06/2010
1	Turcot syndrome 01/2022
1	Stomatitis 01/2021
1	Adenocarcinoma 01/2021
1	Anemia 01/2021
1	Leukopenia 01/2021
1	Rectal Neoplasms (Rectal Cancer) 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Residual Neoplasm 09/2017
1	Fatigue 06/2016
1	Mesothelioma 04/2015
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 08/2013
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/2013
1	Multiple Myeloma 01/2013

Drug/Important Bio-Agent (IBA)

9	ErbB Receptors (EGF Receptor)IBA 01/2022 - 04/2010
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2011
6	Trastuzumab (Herceptin)FDA Link 01/2021 - 11/2015
6	Lapatinib (GW572016)FDA Link 01/2021 - 11/2015
6	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 05/2004
6	Cetuximab (Erbitux)FDA Link 01/2018 - 11/2011
5	Proteins (Proteins, Gene)FDA Link 02/2024 - 06/2011
5	Panitumumab (Vectibix)FDA Link 01/2022 - 07/2015
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2018
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2022 - 01/2020
4	Monoclonal AntibodiesIBA 01/2022 - 04/2010
4	PlatinumIBA 10/2015 - 03/2005
3	Circulating Tumor DNAIBA 11/2023 - 07/2015
3	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2019
3	pertuzumabIBA 01/2021 - 01/2020
3	Capecitabine (Xeloda)FDA Link 01/2021 - 10/2010
3	AntibodiesIBA 01/2019 - 11/2011
2	Calcibiotic Root Canal SealerIBA 01/2023 - 07/2015
2	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 12/2017
2	Sodium Glutamate (Accent)IBA 11/2021 - 01/2021
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 09/2013
2	Proteasome InhibitorsIBA 01/2013 - 06/2012
2	taxaneIBA 06/2012 - 03/2005
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 02/2024
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Thioguanine (Tioguanine)FDA Link 01/2023
1	Cancer VaccinesIBA 01/2023
1	pembrolizumabIBA 01/2022
1	viral interferon regulatory factorsIBA 10/2021
1	Everolimus FDA Link 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	olaparibIBA 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020
1	sotorasibIBA 01/2020
1	trastuzumab deruxtecanIBA 01/2020
1	Ado-Trastuzumab EmtansineIBA 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2020
1	Pregnenolone Carbonitrile (PCN)IBA 01/2019
1	regorafenibIBA 01/2019
1	human ERBB2 proteinIBA 01/2018
1	Cell-Free Nucleic AcidsIBA 09/2017
1	BilirubinIBA 06/2016
1	Codon (Codons)IBA 06/2016
1	Vorinostat FDA Link 04/2015
1	Docetaxel (Taxotere)FDA Link 09/2013
1	PanobinostatIBA 08/2013
1	Histone Deacetylase InhibitorsIBA 08/2013
1	Peptides (Polypeptides)IBA 01/2013
1	Boronic AcidsIBA 01/2013
1	delanzomibIBA 01/2013
1	liposomal doxorubicin (Doxil)FDA Link 06/2012
1	Bortezomib (Velcade)FDA Link 06/2012

Therapy/Procedure

19	Therapeutics 01/2023 - 04/2010
8	Drug Therapy (Chemotherapy) 01/2022 - 01/2003
3	Retreatment 11/2023 - 02/2019
3	Precision Medicine 11/2019 - 01/2011
2	Continuity of Patient Care 11/2023 - 01/2023
2	Immunotherapy 01/2022 - 02/2019
2	Adjuvant Chemotherapy 01/2021 - 05/2004
2	Aftercare (After-Treatment) 01/2019 - 03/2005
2	Neoadjuvant Therapy 01/2011 - 06/2010
1	Secondary Prevention 01/2023
1	Intravenous Administration 01/2013